The FDA cleared the investigational new drug application of IDE849, a potential first-in-class DLL3-targeted antibody-drug ...

Colin P.N. Dinney, MD, provides some background on translational analyses from the BOND-003 and CORE-001 trials.

For those of us who have been in the field for decades, this cycle of exhilaration or despair is common and manageable, but recent months have raised even further uncertainty about how progress in ...

Nicole A. Cipriani, explores the clinical relevance of the BRAF p.V600E mutation in papillary thyroid carcinoma and its potential role in guiding treatment decisions.

ADRX-0706, a Nectin-4-targeted antibody-drug conjugate, has earned FDA fast track designation in advanced cervical cancer.

The anti-GD2 therapy naxitamab has been included in the NCCN Clinical Practice Guidelines in Oncology for the treatment of ...

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials ...

Avutometinib given with defactinib is now approved for the treatment of adult patients with recurrent low-grade serous, ...

Stuart J. Schnitt, MD, discussed artificial intelligence enhancements roadblocks, and potential integration for cancer ...

The FDA granted fast track status to givinostat for treating high-risk polycythemia vera, supporting its potential shown in ...

Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs ...

In a first-of-its-kind procedure, Ruben Olivares, MD, urologist at Cleveland Clinic, supported a robotic-assisted focal therapy for prostate cancer happening in Abu Dhabi from the US. The procedure ...